Bioptik Technology

Bioptik Technology AAQS

The The AAQS of Bioptik Technology (4161.TWO) as of Nov 1, 2026 is 2. In the previous year, The AAQS was 2.00 — a change of 0.00% (lower).

AAQS

2

YoY

0.00%

Last updated:

Bioptik Technology has a current AAQS of 2.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock Bioptik Technology in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

The Bioptik Technology AAQS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

AAQS
Date
AAQS
Jan 1, 2018
2.00 TWD
Jan 1, 2019
2.00 TWD
Jan 1, 2020
2.00 TWD
Jan 1, 2021
2.00 TWD
Jan 1, 2022
2.00 TWD
Jan 1, 2023
2.00 TWD
Jan 1, 2024
2.00 TWD
Jan 1, 2025
2.00 TWD
The Bioptik Technology AAQS history
YEARAAQSYoY
20.00%
20.00%
20.00%
20.00%
20.00%
20.00%
20.00%
20.00%
20.00%
20.00%
20.00%
2—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bioptik Technology Stock analysis

What does Bioptik Technology do? Bioptik Technology, Inc. generates revenue through the sale of hyaluronic acid-based skincare products and medical diagnostic equipment. The company sells multifunctional blood sugar, cholesterol, uric acid, and heme detectors under the Easy Mate and Easy Touch brands, along with testing paper products for these parameters. Its cosmetic line, distributed under ACUREAL, includes toning lotions, essences, facial masks, and face cleaning products. Domestic and international markets are the primary sales channels for both product categories. The firm targets healthcare providers and consumers seeking at-home medical monitoring solutions through its Easy Mate and Easy Touch devices. ACUREAL skincare products appeal to customers interested in biological and medical cosmetics for daily skincare routines. Bioptik Technology focuses on the domestic market and overseas markets for product distribution, ensuring broad accessibility across different regions. Easy Mate and Easy Touch are the key medical equipment brands, while ACUREAL represents the cosmetic segment. The company's product portfolio combines medical diagnostics with skincare, serving two distinct consumer segments: health-conscious individuals monitoring vital metrics and users seeking specialized skincare solutions. This dual approach allows Bioptik Technology to leverage its research and development capabilities across both medical and cosmetic applications. Bioptik Technology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bioptik Technology stock

The AAQS of Bioptik Technology is 2 in 2025.

On Eulerpool you can find the complete historical development of The AAQS Bioptik Technology since 2006 – with annual values, charts, and detailed analysis.

The AAQS is a key figure developed by AlleAktien.

The AAQS is a key figure developed by AlleAktien.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Bioptik Technology

All Key Metrics — Bioptik Technology